This is the new alpha: Autonomously powered human augmentation.
The real leverage is not the vision regained; it's the 2 X 2-millimeter power source.
Miniaturization is the future of wealth 🤗
#BioTech #ExponentialTech #Miniaturization
A tiny wireless eye implant has enabled people to regain partial central vision and read.
A miniature 2×2-millimeter photovoltaic retinal implant, known as PRIMA, has helped dozens of patients with advanced geographic atrophy from dry age-related macular degeneration regain some central vision, enabling many to read letters, words, and numbers.
In a multicenter European trial published in The New England Journal of Medicine, 38 individuals with profound central vision loss received the subretinal implant. At the one-year mark, 81% of the 32 evaluable participants achieved clinically significant improvements—equivalent to gaining about two lines on an eye chart—with many successfully using the device at home for reading tasks.
The fully wireless system pairs the implant, featuring 381 photovoltaic pixels, with specialized glasses equipped with a camera. These glasses project near-infrared light patterns onto the chip, which converts them into electrical pulses to activate remaining retinal neurons.
Safety assessments concluded that benefits outweighed predominantly mild surgical complications, prompting developer Science Corporation to seek European regulatory approval.
That said, the prosthetic vision remains restricted: monochromatic, slow for reading, and requiring extensive user training. It also failed to yield measurable gains in overall quality of life. Critics, including an independent expert, noted the absence of a randomized control arm might inflate perceived benefits, though other ophthalmologists commended the trial's rigor.
Ongoing research targets improved versions with higher pixel density, finer resolution, potential color restoration, and applicability to conditions like retinitis pigmentosa.
[Frank G. Holz, et al., "Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD", New England Journal of Medicine, 2025, DOI: 10.1056/NEJMoa2501396]